2023 Annual Meeting | C163 - Neurologic Complications of Novel Anti-neoplastic Therapies Including Immunotherapy

Date Wednesday 04/26/23

Time 01:00 PM - 03:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Yazmin Odia, MD, MS, FAAN, FAAN

Topic(s) Neuro-oncology

Learning Objectives Participants should become familiar with the distinct types of anti-neoplastic therapies, including cytotoxic, biologic, hormone, immunotherapy, radiation and other multimodal therapies, and their unique neurologic complications, as well as understand the underlying mechanisms of actions, interpret clinical and radiographic manifestations, and manage the neurological toxicities relative to the distinct types of anti-neoplastic therapies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
01:00 PM - 01:05 PM EST	Introduction	Introduction to Course and Novel Cancer Therapies Yazmin Odia, MD, MS, FAAN, FAAN
01:05 PM - 01:35 PM EST	Speaker	Complications of Cytotoxic, Biologic, and Hormone Therapies Na Tosha N. Gatson, MD, PhD, FAAN
01:35 PM - 02:05 PM EST	Speaker	Complications of Immunotherapies Reena P. Thomas, MD, PhD, FAAN
02:05 PM - 02:45 PM EST	Speaker	Complications of Radiation and Multimodal Therapies Yazmin Odia, MD, MS, FAAN, FAAN
02:45 PM - 03:00 PM EST	Speaker	Case Panel Discussions Yazmin Odia, MD, MS, FAAN, FAAN, Na Tosha N. Gatson, MD, PhD, FAAN, Reena P. Thomas, MD, PhD, FAAN

Faculty Disclosures
Yazmin Odia, MD, MS, FAAN, FAAN	Dr. Odia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile. Dr. Odia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chimeric, part of Jazz Pharmaceuticals.
Na Tosha N. Gatson, MD, PhD, FAAN	Dr. Gatson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GT Medical Technologies. Dr. Gatson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Menarini Silicon Biosystems. Dr. Gatson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NuvOx Pharmaceuticals. Dr. Gatson has received publishing royalties from a publication relating to health care. Dr. Gatson has a non-compensated relationship as a Board Member with Society for Equity in Neurosciences (SEQUINS) that is relevant to AAN interests or activities.
Reena P. Thomas, MD, PhD, FAAN	The institution of Dr. Thomas has received research support from NIH. The institution of Dr. Thomas has received research support from California Institute of Regenerative Medicine. Dr. Thomas has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��